Thursday, September 26, 2019 10:15:20 AM
___________________________________________________________________________________________________
Historic short interest:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151367871
Chart illustration of shares shorted summer 2019
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151145245
Historical chart study comparing AVXL to AMRN and ARWR
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150959901
Comment on the above:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150960121
9/16/19 observation on options movement
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151152660
AMRN - AVXL stock comparison:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145046917
"Anavex in Five Years", perspective from falconer66a
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148898022
Will Anavex business model include a novel development in precision medicine?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148557900
Discussion on 4/25/19 concerning new blood tests for Alzheimer's - read forward from here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148425843
How the pros take out stops...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150305491
Missling expertise in M&A roundtable :
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150852768
Anavex in stealth mode:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150311481
Evaluation of market cap potential of AVXL:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143725918
Interesting look at what was expected of AVXL in 11/14:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148475152
Retrospective look at Missling's appointment as CEO:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148475334
2015 interview of Missling stating that knowledge will be the goal of the 2a adaptive trial which will increase our chance of success:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148475720
Prediction that AVXL would reverse Alzheimer's from 2013:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148475575
Missling without quite so much hair here:
http://spotlightonbioadvances.homestead.com/Case-Study.html
How Missling is using the old FDA process to create new precision medicine processes:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148611726
Biostock's AI program estmates 89% chance of approval:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148688289
Little Orphan Anavex - a 2016 post...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=122025509
Historical short interest:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145900941
Hint at actual AVXL value:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147273799
F1ash statements on the Cantor ATM:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146081099
Charts showing periods of institutional accumulation:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144037184
Gross market estimates from falconer66a:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145757480
Pharma growth predictions (from Talon38)
https://www.biospace.com/article/deloitte-predicts-pharma-growth-driven-by-orphan-disease-drugs-and-external-deals
MycrolftHolmes on Barriers to investment in AVXL:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135326763
Short interest note from georgejjl:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147068381
Perspective on how quickly Anavex could morph into a profitable entity , making further dilution unnecessary. This may provide urgency for institutions to establish a position where stock has limited liquidity resulting in a pre-approval ramp up of pricing.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143560772
Recent AVXL News
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- The Gross Law Firm Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 03/22/2024 09:45:00 AM
- Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 03/18/2024 11:30:00 AM
- Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference • GlobeNewswire Inc. • 02/26/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:05:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:06 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/07/2024 09:31:07 PM
- Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/07/2024 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024 • GlobeNewswire Inc. • 02/01/2024 12:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/25/2024 10:01:34 PM
- Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans • GlobeNewswire Inc. • 01/24/2024 12:30:00 PM
- Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 01/16/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 01:00:34 AM
- Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders • GlobeNewswire Inc. • 01/08/2024 12:30:00 PM
- Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/03/2024 12:30:00 PM
- Anavex Life Sciences Provides an Update on Rett Syndrome Program • GlobeNewswire Inc. • 01/02/2024 01:00:00 PM
- Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome • GlobeNewswire Inc. • 12/20/2023 12:30:00 PM
- Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s Disease • GlobeNewswire Inc. • 12/19/2023 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 11/27/2023 09:30:41 PM
- Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/27/2023 01:00:00 PM
- Monday’s Wall Street Highlights: Walmart, Disney, Lloyds Banking, Mitsui Financial, HSBC, and more • IH Market News • 11/27/2023 11:29:25 AM
FEATURED POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • Mar 27, 2024 10:52 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM